Phase I/II trial of EG 011 in patients with angina pectoris.
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2012
At a glance
- Drugs EG 011 (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Sponsors Ark Therapeutics
- 16 May 2012 The phase I dose-ranging component of the trial has completed enrolment; enrolment in the phase IIa stage of the trial is expected to begin in the third quarter of 2012 according to an Ark Therapeutics media release.
- 18 May 2011 Recruitment into the low-dose group has been completed and several patients have been treated with the high dose, according to an Ark Therapeutics media release.
- 28 Jan 2010 The first patient has been enrolled and treated according to an Ark Therapeutics media release.